

B-LCL-HROC112 | 302023

Description
B-LCL-HROC112 B - (EBV) B . A
, B-LCL-HROC112 CD19 CD20 CD23 CD80 B . MH
, B-LCL-HROC112 (: IgG, IgM IgA) , .

Organism
Tissue

Disease
Metastatic site Not applicable (EBV-transformed B-LCL from CRC patient; suspension culture)

Applications T cell and NK cell assays; HLA typing; antigen presentation studies; CTL assay target cells; colorectal cancer immunology; patient-matched HROC biobank studies

Synonyms B-LCL CO112, Bc HROC112

Age 80

Gender
Ethnicity Caucasian

Morphology
Cell type B

Growth properties

Citation B-LCL-HROC112(302023)

B-LCL-HROC112 | 302023

Biosafety level 2

NCBI_TaxID 9606

CellosaurusAccession Not assigned

GMO Status GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.

Viruses : EBV

Culture Medium RPMI 1640, w: 2.0mM , w: 2.0g/L NaHCO3(820700a)

Supplements 10% FBS

Subculturing ⁵ /ml , , ml .. 1 x 10

Freeze medium (FBS) + 10% DMSO , CM-1(Cytion 800100)

B-LCL-HROC112 | 302023

Thawing and Culturing Cells	
1.	.
2.	-150°C , 3 .
3.	37°C 40~60 .
4.	, 70% .
5.	8ml 15ml .
6.	300 x g 3 .
7.	10ml . T25 , T25
8.	.

Incubation Atmosphere 37°C, 5%_{CO2} .

Flask Coating

Freezing Procedure -78°C .

Shipping Conditions -78°C .

Storage Conditions -150°C -196°C .80°C .

/ / HLA

Sterility PCR .